Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma

Steven Brem, Stuart A Grossman, Kathryn Anne Carson, Pamela New, Surasak Phuphanich, Jane B. Alavi, Tom Mikkelsen, Joy D. Fisher

Research output: Contribution to journalArticle

Abstract

Penicillamine is an oral agent used to treat intracerebral copper overload in Wilson's disease. Copper is a known regulator of angiogenesis; copper reduction inhibits experimental glioma growth and invasiveness. This study examined the feasibility, safety, and efficacy of creating a copper deficiency in human glioblastoma multiforme. Forty eligible patients with newly diagnosed glioblastoma multiforme began radiation therapy (6000 cGy in 30 fractions) in conjunction with a low-copper diet and escalating doses of penicillamine. Serum copper was measured at baseline and monthly. The primary end point of this study was overall survival compared to historical controls within the NABTT CNS Consortium database. The 25 males and 15 females who were enrolled had a median age of 54 years and a median Karnofsky performance status of 90. Surgical resection was performed in 83% of these patients. Normal serum copper levels at baseline (median, 130 μg/dl; range, 50-227 μg/dl) fell to the target range of

Original languageEnglish (US)
Pages (from-to)246-253
Number of pages8
JournalNeuro-Oncology
Volume7
Issue number3
DOIs
StatePublished - Jul 2005

Fingerprint

Penicillamine
Glioblastoma
Copper
Therapeutics
Karnofsky Performance Status
Hepatolenticular Degeneration
Feasibility Studies
Serum
Glioma
Radiotherapy
Databases
Diet
Safety
Survival
Growth

Keywords

  • Angiogenesis
  • Brain tumor
  • Copper
  • Glioblastoma
  • Penicillamine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. / Brem, Steven; Grossman, Stuart A; Carson, Kathryn Anne; New, Pamela; Phuphanich, Surasak; Alavi, Jane B.; Mikkelsen, Tom; Fisher, Joy D.

In: Neuro-Oncology, Vol. 7, No. 3, 07.2005, p. 246-253.

Research output: Contribution to journalArticle

Brem, Steven ; Grossman, Stuart A ; Carson, Kathryn Anne ; New, Pamela ; Phuphanich, Surasak ; Alavi, Jane B. ; Mikkelsen, Tom ; Fisher, Joy D. / Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. In: Neuro-Oncology. 2005 ; Vol. 7, No. 3. pp. 246-253.
@article{d35d6a04e0b543d9b03683861bf54a57,
title = "Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma",
abstract = "Penicillamine is an oral agent used to treat intracerebral copper overload in Wilson's disease. Copper is a known regulator of angiogenesis; copper reduction inhibits experimental glioma growth and invasiveness. This study examined the feasibility, safety, and efficacy of creating a copper deficiency in human glioblastoma multiforme. Forty eligible patients with newly diagnosed glioblastoma multiforme began radiation therapy (6000 cGy in 30 fractions) in conjunction with a low-copper diet and escalating doses of penicillamine. Serum copper was measured at baseline and monthly. The primary end point of this study was overall survival compared to historical controls within the NABTT CNS Consortium database. The 25 males and 15 females who were enrolled had a median age of 54 years and a median Karnofsky performance status of 90. Surgical resection was performed in 83{\%} of these patients. Normal serum copper levels at baseline (median, 130 μg/dl; range, 50-227 μg/dl) fell to the target range of",
keywords = "Angiogenesis, Brain tumor, Copper, Glioblastoma, Penicillamine",
author = "Steven Brem and Grossman, {Stuart A} and Carson, {Kathryn Anne} and Pamela New and Surasak Phuphanich and Alavi, {Jane B.} and Tom Mikkelsen and Fisher, {Joy D.}",
year = "2005",
month = "7",
doi = "10.1215/S1152851704000869",
language = "English (US)",
volume = "7",
pages = "246--253",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma

AU - Brem, Steven

AU - Grossman, Stuart A

AU - Carson, Kathryn Anne

AU - New, Pamela

AU - Phuphanich, Surasak

AU - Alavi, Jane B.

AU - Mikkelsen, Tom

AU - Fisher, Joy D.

PY - 2005/7

Y1 - 2005/7

N2 - Penicillamine is an oral agent used to treat intracerebral copper overload in Wilson's disease. Copper is a known regulator of angiogenesis; copper reduction inhibits experimental glioma growth and invasiveness. This study examined the feasibility, safety, and efficacy of creating a copper deficiency in human glioblastoma multiforme. Forty eligible patients with newly diagnosed glioblastoma multiforme began radiation therapy (6000 cGy in 30 fractions) in conjunction with a low-copper diet and escalating doses of penicillamine. Serum copper was measured at baseline and monthly. The primary end point of this study was overall survival compared to historical controls within the NABTT CNS Consortium database. The 25 males and 15 females who were enrolled had a median age of 54 years and a median Karnofsky performance status of 90. Surgical resection was performed in 83% of these patients. Normal serum copper levels at baseline (median, 130 μg/dl; range, 50-227 μg/dl) fell to the target range of

AB - Penicillamine is an oral agent used to treat intracerebral copper overload in Wilson's disease. Copper is a known regulator of angiogenesis; copper reduction inhibits experimental glioma growth and invasiveness. This study examined the feasibility, safety, and efficacy of creating a copper deficiency in human glioblastoma multiforme. Forty eligible patients with newly diagnosed glioblastoma multiforme began radiation therapy (6000 cGy in 30 fractions) in conjunction with a low-copper diet and escalating doses of penicillamine. Serum copper was measured at baseline and monthly. The primary end point of this study was overall survival compared to historical controls within the NABTT CNS Consortium database. The 25 males and 15 females who were enrolled had a median age of 54 years and a median Karnofsky performance status of 90. Surgical resection was performed in 83% of these patients. Normal serum copper levels at baseline (median, 130 μg/dl; range, 50-227 μg/dl) fell to the target range of

KW - Angiogenesis

KW - Brain tumor

KW - Copper

KW - Glioblastoma

KW - Penicillamine

UR - http://www.scopus.com/inward/record.url?scp=23144467529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23144467529&partnerID=8YFLogxK

U2 - 10.1215/S1152851704000869

DO - 10.1215/S1152851704000869

M3 - Article

VL - 7

SP - 246

EP - 253

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 3

ER -